TNFSF11 and lung cancer: As the first fully human anti-RANKL mAb, denosumab was demonstrated to be non-inferior to zoledronic acid (ZA) in delaying time to the first on-study skeletal-related events (SREs) in a randomized, double-blind study enrolling multiple advanced cancer types (including lung cancer) (8) and has been approved by the FDA for preventing SREs in solid tumors.